argenx SE
F:1AEA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
argenx SE
F:1AEA
|
NL |
|
K
|
Kyudenko Corp
OTC:KYDKF
|
JP |
|
T
|
Teck Resources Ltd
TSX:TECK.B
|
CA |
|
A
|
AltaGas Ltd
OTC:ATGFF
|
CA |
|
Karooooo Ltd
NASDAQ:KARO
|
SG |
|
Oxford Square Capital Corp
F:22T
|
US |
|
V
|
Visa Inc
LSE:0QZ0
|
US |
|
L
|
LyondellBasell Industries NV
SWB:DLY
|
UK |
|
Siriuspoint Ltd
NYSE:SPNT
|
BM |
|
M
|
Mesoblast Ltd
OTC:MEOBF
|
AU |
|
B
|
Bank Central Asia Tbk PT
XBER:BZG2
|
ID |
|
G
|
GoGold Resources Inc
F:GGD
|
CA |
|
S
|
Spero Therapeutics Inc
F:2HA
|
US |
|
P
|
Pagegroup PLC
OTC:MPGPF
|
UK |
|
Siemens Healthineers AG
LSE:0PMJ
|
DE |
|
CVR Energy Inc
LSE:0HRR
|
US |
|
O
|
Okta Inc
F:0OK
|
US |
|
L
|
Lineage Cell Therapeutics Inc
XBER:BT3
|
US |
|
H
|
Hays PLC
XBER:HAY
|
UK |
|
Q
|
QinetiQ Group PLC
XMUN:QY6
|
UK |
|
Chailease Holding Company Ltd
TWSE:5871
|
TW |
|
S
|
Smith Micro Software Inc
F:SS91
|
US |
|
V
|
Volkswagen AG
DUS:VOW
|
DE |
|
M
|
MakeMyTrip Ltd
F:MY1
|
IN |
argenx SE
argenx is a biotechnology company that develops antibody-based medicines for serious autoimmune diseases, where the body attacks its own tissues. Its best-known product is VYVGART, a prescription therapy used by specialist doctors and hospitals to treat certain immune disorders. The company also has a pipeline of follow-on drug candidates built around the same antibody engineering platform. The people who ultimately use argenx’s medicines are patients with rare or hard-to-treat autoimmune conditions, but the company sells through the healthcare system: physicians prescribe the drugs, pharmacies and specialty distributors handle delivery, and insurers or government health programs often pay for them. argenx makes money mainly by selling approved medicines and, in some cases, by earning collaboration or royalty income from partners. What makes argenx different is that it focuses on a narrow set of immune diseases and builds drugs around a common scientific idea rather than spreading across many therapy areas. That gives it a clear role in the drug value chain: it turns lab research into specialty medicines that larger healthcare systems and specialist doctors can use for patients with few good treatment options.
argenx is a biotechnology company that develops antibody-based medicines for serious autoimmune diseases, where the body attacks its own tissues. Its best-known product is VYVGART, a prescription therapy used by specialist doctors and hospitals to treat certain immune disorders. The company also has a pipeline of follow-on drug candidates built around the same antibody engineering platform.
The people who ultimately use argenx’s medicines are patients with rare or hard-to-treat autoimmune conditions, but the company sells through the healthcare system: physicians prescribe the drugs, pharmacies and specialty distributors handle delivery, and insurers or government health programs often pay for them. argenx makes money mainly by selling approved medicines and, in some cases, by earning collaboration or royalty income from partners.
What makes argenx different is that it focuses on a narrow set of immune diseases and builds drugs around a common scientific idea rather than spreading across many therapy areas. That gives it a clear role in the drug value chain: it turns lab research into specialty medicines that larger healthcare systems and specialist doctors can use for patients with few good treatment options.
Strong growth: Argenx reported first-quarter product net sales of $1.3 billion, up 63% year over year, with management saying demand trends remain very strong despite typical seasonality.
VYVGART momentum: New patient starts were among the highest since launch, and management highlighted continued growth in MG and CIDP, helped by the prefilled syringe and earlier-line use.
Near-term catalysts: The company is days away from a May 10 PDUFA decision for seronegative MG, with ocular MG filing expected next and pediatric MG still on the roadmap.
Pipeline breadth: Argenx pointed to a busy second half, led by the Phase III myositis readout in Q3, empasiprubart in MMN in 4Q, and other pipeline expansion plans.
Profitability: Operating profit reached $394 million with a 30% operating margin, and management said the company remains on track for continued margin expansion as revenue grows faster than spending.
Capital deployment: With $4.9 billion in cash, the company said it has room to keep investing in internal innovation, supply chain, and business development, including more strategic investments like Forte.
Competition view: Management said rivals are mostly showing up in later lines, while VYVGART remains positioned earlier in treatment and continues to benefit from physician confidence and broad prescriber adoption.
